ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Snowflake Inc

Snowflake Inc (SNOW)

127.60
-3.07
(-2.35%)
Closed June 19 4:00PM
127.30
-0.30
(-0.24%)
After Hours: 7:59PM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
127.30
Bid
-
Ask
-
Volume
5,982,790
126.56 Day's Range 131.1384
124.69 52 Week Range 237.72
Market Cap
Previous Close
130.67
Open
130.11
Last Trade
1
@
127.33
Last Trade Time
Financial Volume
$ 767,259,314
VWAP
128.2444
Average Volume (3m)
5,723,178
Shares Outstanding
329,300,000
Dividend Yield
-
PE Ratio
-50.26
Earnings Per Share (EPS)
-2.54
Revenue
2.81B
Net Profit
-836.1M

About Snowflake Inc

Snowflake delivers the Data Cloud a global network where thousands of organizations mobilize data with near-unlimited scale concurrency and performance. Inside the Data Cloud organizations unite their siloed data easily discover and securely share governed data and execute diverse analytic workloads... Snowflake delivers the Data Cloud a global network where thousands of organizations mobilize data with near-unlimited scale concurrency and performance. Inside the Data Cloud organizations unite their siloed data easily discover and securely share governed data and execute diverse analytic workloads. Wherever data or users live Snowflake delivers a single and seamless experience across multiple public clouds. Snowflakes platform is the engine that powers and provides access to the Data Cloud creating a solution for data warehousing data lakes data engineering data science data application development and data sharing. Join Snowflake customers partners and data providers already taking their businesses to new frontiers in the Data Cloud. Show more

Sector
Prepackaged Software
Industry
Prepackaged Software
Headquarters
Wilmington, Delaware, USA
Founded
1970
Snowflake Inc is listed in the Prepackaged Software sector of the New York Stock Exchange with ticker SNOW. The last closing price for Snowflake was $130.67. Over the last year, Snowflake shares have traded in a share price range of $ 124.69 to $ 237.72.

Snowflake currently has 329,300,000 shares outstanding. The market capitalization of Snowflake is $42.02 billion. Snowflake has a price to earnings ratio (PE ratio) of -50.26.

Snowflake (SNOW) Options Flow Summary

Overall Flow

Bearish

Net Premium

-196M

Calls / Puts

65.26%

Buys / Sells

104.88%

OTM / ITM

53.71%

Sweeps Ratio

0.00%

SNOW Latest News

Fisker Files for Bankruptcy, Chegg Stocks Rise on 23% Workforce Reduction, and More

Fisker (NYSE:FSR) – The American electric vehicle manufacturer filed for bankruptcy last night, aiming to sell its assets and restructure debts following severe financial challenges in the...

Adobe Soars 15% Pre-Market; Visa and Mastercard Encounter Hurdles in $30 Billion Agreement, and More

Adobe (NASDAQ:ADBE) – Adobe exceeded expectations in the last quarter with revenue of $5.31 billion, above analysts’ consensus polled by FactSet of $5.29 billion. Adjusted earnings...

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CMTLComtech Telecommunications Corporation
$ 4.07
(87.56%)
91.43M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.36M
ASNSActelis Networks Inc
$ 2.11
(83.48%)
51.37M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
LRHCLa Rosa Holdings Corporation
$ 1.78
(71.15%)
52.9M
STISolidion Technology Inc
$ 0.6881
(-64.35%)
16.36M
DMTKDermTech Inc
$ 0.1488
(-55.25%)
10.74M
QMCOQuantum Corporation
$ 0.3752
(-51.90%)
3.14M
ZNTLZentalis Pharmaceuticals Inc
$ 4.135
(-50.72%)
21.58M
AWINAERWINS Technologies Inc
$ 1.74
(-47.90%)
1.05M
RELIReliance Global Group Inc
$ 0.40
(80.18%)
394.85M
NLSPNLS Pharmaceutics Ltd
$ 0.2735
(84.42%)
305.35M
NVDANVIDIA Corporation
$ 135.58
(3.51%)
294.32M
MBIOMustang Bio Inc
$ 0.8517
(13.56%)
291.95M
CRKNCrown Electrokinetics Corporation
$ 0.0548
(-17.10%)
92.39M

SNOW Discussion

View Posts
Chart Reader Chart Reader 2 weeks ago
I added additional shares today at 129.55.

The reason for the weakness today was that several companies reported changes to their fundamental outlook, with one company lowering the upside objective from $207 to $186. Nonetheless, several companies maintained their upside objective at $210 and on company (Piper Jeffries) maintained a $240 upside objective.

Nonetheless, the bears took this opportunity to push down to try to trigger stop losses. There is/was an important intraweek support at 128.56 that they targeted for breakage and they were successful in breaking it as the low today has been 128.43. Nonetheless, it is evident that level was targeted on pure manipulation of the prices as the minute it was broken, there was no additional selling and immediately thereafter and in using the 1-minute chart, the down move was negated with a $2.30 move up from the low in just 20 minutes, meaning the low for the day (and probably for this entire move down) a low has been set. This stock should now begin to rally from here on in, suggesting that today is the best time to purchase the stock.

and by the way, NVDA made another new all-time high today. The AI story stays true.
👍️0
Chart Reader Chart Reader 2 weeks ago
I purchased SNOW at 133.98 on Friday. Stop loss is at 128.46 and objective of 207.45. I am risking $552 to pick up $7347 (per 100 shares). It is a 13-1 risk/reward ratio (based on established support and resistance levels). I consider this trade a "must do trade"
👍️0
Tiger Money Tiger Money 3 weeks ago
Far enough now?
👍️0
WallWeeD WallWeeD 3 months ago
I will wait until after the pullback
👍️0
letsrunthis letsrunthis 3 months ago
why?
👍️0
WallWeeD WallWeeD 4 months ago
Yeah hmm no
👍️0
blue finch blue finch 4 months ago
time to load up here
👍️0
Monksdream Monksdream 4 months ago
SNOW new 52 week high
👍️0
Monksdream Monksdream 4 months ago
SNOW new 52 week high
👍️0
cheynew cheynew 4 months ago
NOVO HOLDINGS TO ACQUIRE CATALENT

Catalent Stockholders to Receive $63.50 Per Share in Cash, Representing a 47.5% Premium to the 60-day Volume-Weighted Average Price as of February 2, 2024

Catalent, Inc. (NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, today announced that they have entered into a merger agreement under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.

Transaction Overview

Novo Holdings will acquire all outstanding shares of Catalent for $63.50 per share in cash. The purchase price represents a premium of 16.5% to the closing price of Catalent’s common stock as of February 2, 2024, the last trading day prior to this announcement, and a 47.5% premium to the 60-day volume-weighted average price as of February 2, 2024.
In addition, the purchase price represents a premium of 39.1% to the closing price of Catalent’s common stock on August 28, 2023, the last trading day prior to Catalent’s announcement that its Board of Directors formed a Strategic and Operational Review Committee to conduct a review of Catalent’s business, strategy and operations, as well as Catalent’s capital-allocation priorities with a view towards maximizing value for all Catalent stockholders.
Of Catalent’s more than 50 global sites, Novo Holdings intends to sell three Catalent fill-finish sites and related assets acquired in the merger to Novo Nordisk (CPH: NOVO), in which Novo Holdings has a controlling interest, shortly after the closing of the merger. These three sites are located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium.
This transaction is aligned with Novo Holdings’ strategy of investing in established life science companies with strong long-term potential.
Alessandro Maselli, President and Chief Executive Officer of Catalent, said: “Over the past several years, Catalent has built a comprehensive end-to-end offering of services and capabilities to drive innovation in the healthcare system and improve patient outcomes. This transaction is a testament to our team’s hard work and dedication to this mission, and I am incredibly excited for this next step in our journey. We look forward to benefiting from Novo Holdings’ significant resources to accelerate investment in our business and enhance key offerings as we continue to offer premium development and manufacturing solutions for pharma and biotech customers.”

John Greisch, Executive Chair of the Catalent Board and Chair of the Strategic and Operational Review Committee, said: “This transaction delivers significant, certain and premium value to our stockholders. Novo Holdings believes in our vision and will provide Catalent with a strong foundation as we continue developing, manufacturing and supplying top products.”

Novo Holdings has a proven track record of successfully investing in the life sciences sector. Importantly, Novo Holdings’ purpose is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Kasim Kutay, CEO of Novo Holdings, said: “We are excited to partner with Catalent as it enters a new phase of growth and accelerates its mission to develop, manufacture and supply products that help people live better and healthier lives. With our expertise and track record of investing in high quality life sciences businesses, we believe Catalent is a very good strategic fit. We are excited to support the Company’s stakeholders in the years ahead, especially employees and customers as they work to develop new products to benefit patients. As engaged investors committed to productive relationships with all our partners, we look forward to working with the Catalent team to realise the Company’s full potential.

Importantly, our acquisition of Catalent is aligned with our mandate to invest in high quality life sciences companies for the benefit of the Novo Nordisk Foundation’s mission and philanthropic causes.”

Marc Steinberg, Partner at Elliott Investment Management L.P., said: “As a significant investor in Catalent, Elliott fully supports the transaction announced today. We believe that this transaction, which is the culmination of a process led by the Strategic and Operational Review Committee of the Catalent Board, clearly maximizes value for Catalent stockholders. We commend Catalent’s Board and management team for delivering this outstanding outcome.”

Transaction Details

The merger is expected to close towards the end of calendar year 2024, subject to customary closing conditions, including approval by Catalent stockholders and receipt of required regulatory approvals. The transaction is not subject to any financing contingency.

Following an evaluation of possible value-maximizing alternatives, the Catalent Board unanimously determined that the transaction with Novo Holdings, which delivers a premium and certain cash value, is in the best interest of Catalent. Accordingly, the Catalent Board unanimously recommends that Catalent stockholders vote in favor of the merger.

In addition, Elliott Investment Management L.P. and certain of its affiliates have entered into a support agreement pursuant to which they have agreed to vote their shares of Catalent common stock in favor of the merger.

Following the closing of the merger, shares of Catalent will no longer trade on the New York Stock Exchange and Catalent will become a private company.

Second Quarter 2024 Financial Results

Catalent’s second quarter 2024 earnings results are expected to be issued on February 9, 2024. In light of the announced transaction, Catalent will not host an earnings conference call. Catalent’s second quarter 2024 earnings press release will be available on its investor relations website at http://investor.catalent.com .

Advisors

Citi and J.P. Morgan are acting as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor to Catalent and Jones Day is serving as legal advisor to the Catalent Board of Directors. Morgan Stanley is acting as financial advisor to Novo Holdings and Goodwin Procter LLP is serving as legal advisor to Novo Holdings.

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seeds, Venture, Growth, and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development.

As of year-end 2022, Novo Holdings had total assets of EUR 108 billion.
www.novoholdings.dk

About the Novo Nordisk Foundation

Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people’s health and the sustainability of society and the planet. The Foundation’s mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
www.novonordiskfonden.dk/en

About Catalent

Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, Catalent is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. Catalent helps accelerate over 1,500 partner programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply approximately 70 billion doses of nearly 8,000 products annually. Catalent’s expert workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated nearly $4.3 billion in revenue in its 2023 fiscal year.
👍️0
Mt. Blanc Mt. Blanc 4 months ago
SNOW has been on a tear.

CTLT gets bought out.

mb
👍️0
Monksdream Monksdream 4 months ago
SNOW new 52=week high
👍️0
TheFinalCD TheFinalCD 10 months ago
SNOW NVDA
👍️0
BottomBounce BottomBounce 11 months ago
Snowflake Inc. $SNOW Total Debt (mrq) $254.84M
👍️0
alchemytrader alchemytrader 1 year ago
150.00 now...never say never.
👍️0
$Pistol Pete$ $Pistol Pete$ 1 year ago
Nice close man…I am heavy invest into this one
👍️0
$Pistol Pete$ $Pistol Pete$ 1 year ago
I don’t think it will get below $120 again. Maybe in our dream though
👍️0
alchemytrader alchemytrader 1 year ago
wait for 120.00 to be interested.
👍️0
$Pistol Pete$ $Pistol Pete$ 1 year ago
Buy the dip man
👍️0
$Pistol Pete$ $Pistol Pete$ 1 year ago
Holding strong here
👍️0
StockLogistics StockLogistics 2 years ago
This stock is called “snow” and SP increases from May till early December, before winter begins in the U.S.., it appears. That is some sort of counter trend to the idea of snowing.
👍️0
Liam859 Liam859 2 years ago
$SNOW $128 I loaded so you can dump on me now
👍️0
alchemytrader alchemytrader 2 years ago
Calls babyyyy$$$$


OMG...RIP!
👍️0
alchemytrader alchemytrader 2 years ago
SNOW melted again.
👍️0
Porterhouse10 Porterhouse10 2 years ago
Down goes Balboa! Yo Adrian!
👍️0
Porterhouse10 Porterhouse10 2 years ago
It just Did!
👍️0
bcapps66 bcapps66 2 years ago
Looking at the price drop the last few days that should have read "CRIES babyyyy" LOL!
👍️0
IVANj IVANj 2 years ago
Calls babyyyy$$$$
👍️0
bcapps66 bcapps66 2 years ago
Wow! Just...wow
👍️0
bcapps66 bcapps66 2 years ago
Ouch!!! Wicked haircut!
👍️0
Prudent Capitalist Prudent Capitalist 2 years ago
If increasing revenue by 101% over the previous comparable quarter and improving the bottom line is bad, then Houston, we have a problem. It appears that the problem was disappointing forward guidance that did not match Wall Street expectations. SNOW is a screaming buy down here for long term investors, e.g. this am Cowen & Co. maintained its outperform rating but lowered its price target for SNOW to $390. Several firms still have price targets in the high $300's for SNOW, even after adjustments since the release last evening. I sure wouldn't sell any SNOW shares down here.
👍️0
alchemytrader alchemytrader 2 years ago
WOW! -30% drop after hours on bad earnings!
👍️0
ThatHawaiiGuy ThatHawaiiGuy 3 years ago
WOW! +50% since i started watching this bad dog....
👍️0
BottomBounce BottomBounce 3 years ago
$SNOW Total Debt (mrq) $200.53M
Book Value Per Share (mrq) $16.76
https://finance.yahoo.com/quote/SNOW/key-statistics?p=SNOW
👍️0
WealthyKing WealthyKing 3 years ago
Come on snow! 100 calls @240 expiring today ...
👍️0
WealthyKing WealthyKing 3 years ago
I was 5 days off on my ask for $270, too bad I was holding such near term options that went worthless...thanks for the reminder
👍️0
Reversemergers Reversemergers 3 years ago
I want 270 tomorrow too
👍️0
Nunngoy Nunngoy 3 years ago
King -- sorry for the loss - nobody else has the B ____S to admit it - GET IT BACK !
👍️0
Nunngoy Nunngoy 3 years ago
King -- sorry for the loss - nobody else has the B ____S to admit it - GET IT BACK !
👍️0
WealthyKing WealthyKing 3 years ago
And back down $snow goes. Can we please see 270 tomorrow
👍️0
WealthyKing WealthyKing 3 years ago
Snow may be bucking the trend here, time to move back up
👍️0
TheSprinx TheSprinx 3 years ago
Snowflake Data Marketplace Expands Total Providers Over 300%, Unlocking More Value for Thousands of Organizations!!!!
Boom
👍️0
WealthyKing WealthyKing 3 years ago
I'd love to see them dump 15 million today or tomorrow
👍️0
zatafour zatafour 3 years ago
SNOW... loading up puts, the locked up shares are in the process of being cleared by brokers
👍️0
WealthyKing WealthyKing 3 years ago
Sold my call options for loss yesterday thinking today would be big red day...this sucks
👍️0
WealthyKing WealthyKing 3 years ago
My put options went from big green to 95% loss today...friggin bs
👍️0
Pisd Pisd 3 years ago
Made money.. sold remaining shares today ..watch list SNOW$...



👍️0
WealthyKing WealthyKing 3 years ago
What a bunch of bs today...
👍️0
Pisd Pisd 3 years ago
Snowflake Lockup to End Early for Some Shares. A Blizzard of Selling Is Possible. -- Barrons.com

Today 2:22 PM ET (Dow Jones)Print


By Eric J. Savitz

Snowflake could be headed for an avalanche of insider selling.

In a securities filing late last week, the cloud-based data warehouse company disclosed that the huge run-up in its stock price following its initial public offering had triggered a provision in its lockup agreement with the company's officers, directors, and early shareholders to allow a quarter of those holdings to trade.

Terms of the deal required that Snowflake (ticker: SNOW) trade 133% above the company's $120 IPO price for at least 10 days in a 15-day period. That requirement was fulfilled on Dec. 29, and 37.9 million previously locked-up Snowflake shares will be free to trade on Thursday.

Note that the company issued 28 million shares in its September IPO. An initial tranche of previously locked-up stock became free-trading on Dec. 15.

Snowflake shares, while still well above the original IPO price, have come back a little closer to terra firma. The stock opened for trading on Sept. 16 at $245, then closed at $253.93. As recently as a month ago, the stock traded as high as $429 on an intraday basis, but it has since been gradually ebbing, closing on Monday at $278.24.

Snowflake has slipped about 14% since the first tranche of insider shares was freed up for trading.

In a research note Tuesday, Deutsche Bank analyst Patrick Colville repeated his Hold rating, cutting his price target on the stock to $335, from $270. He estimates that the additional shares to be freed this week will increase the free float in Snowflake shares by 87%.

"With Snowflake stock up almost 133% from its IPO price, we expect some investors to cash out as lockups expire," he wrote. "This could weigh on share price accretion from here."


But in trading Tuesday, Snowflake was actually up 1.6%, to $282.74.


Write to Eric J. Savitz at eric.savitz@barrons.com

(END) Dow Jones Newswires

January 05, 2021 14:22 ET (19:22 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
👍️0
Pisd Pisd 3 years ago
Doubled down here $292, might hold on.. SNOW$...


👍️0